Dr. Lon D. Lynn

Family Medicine
3910 Northdale Blvd Ste 206, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
3910 Northdale Blvd Ste 206, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lon Lynn is a primary care provider, practicing in Family Medicine in Tampa, Florida. His top areas of expertise are Diabetic Neuropathy, Peripheral Neuropathy, Infant Hyperglycemia, and Cramp-Fasciculation Syndrome. Dr. Lynn is currently accepting new patients.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

3910 Northdale Blvd Ste 206, Tampa, FL 33624

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic Pain
An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic Pain
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Qutenza (Capsaicin) 8% Topical System, Capsaicin 0.04% Topical System
Study Phase: Phase 3
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other, Biological
Study Phase: Phase 3
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Biological, Other
Study Drug: Engensis
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: LY3361237
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty
A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
65
conditions
Dr. Ghulam M. Anwar
Family Medicine
Expertise in
65
conditions
Dr. Ghulam M. Anwar
Family Medicine
1936 Bruce B Downs Blvd, Suite 312, 
Wesley Chapel, FL 
 (12.9 miles away)
352-350-3440
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ghulam Anwar is a primary care provider, practicing in Family Medicine in Wesley Chapel, Florida. Dr. Anwar is highly rated in 65 conditions, according to our data. His top areas of expertise are Sepsis, Necrosis, Heart Attack, Ureteroscopy, and Endoscopy. Dr. Anwar is currently accepting new patients.

Expertise in
102
conditions
Dr. Timothy S. Bailey
Family Medicine | Internal Medicine
Expertise in
102
conditions
Dr. Timothy S. Bailey
Family Medicine | Internal Medicine

Sports And Orthopedic Rehabilitation Services Inc

5347 Main St, Suite 202, 
New Port Richey, FL 
 (16.8 miles away)
727-841-0515
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Bailey is a primary care provider, practicing in Family Medicine and Internal Medicine in New Port Richey, Florida. Dr. Bailey is highly rated in 102 conditions, according to our data. His top areas of expertise are Opioid Induced Constipation, Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, and Hyperlipoproteinemia Type 4. Dr. Bailey is currently accepting new patients.

Expertise in
86
conditions
Dr. Vincent J. Dilella
Family Medicine
Expertise in
86
conditions
Dr. Vincent J. Dilella
Family Medicine

V.J. Dilella, D.O., L.L.C.

703 Virginia St, 
Dunedin, FL 
 (16.1 miles away)
727-734-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vincent Dilella is a primary care provider, practicing in Family Medicine in Dunedin, Florida. Dr. Dilella is highly rated in 86 conditions, according to our data. His top areas of expertise are Anemia, Dementia, Urinary Tract Infection in Children, and Carbamoyl Phosphate Synthetase 1 Deficiency. Dr. Dilella is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lynn's expertise for a condition
ConditionClose
        View All 11 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile